Janux Therapeutics, Inc. SEC filings JANX

Janux Therapeutics, Inc. has 442 filings in SEC EDGAR's recent list, going back to Jul 14, 2020. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.

Janux Therapeutics, Inc. SEC filings
Form Description Filed Period
10-Q Quarterly report Nov 5, 2026 Sep 30, 2026
8-K Current report
Results of operations
Nov 5, 2026 Nov 5, 2026
10-Q Quarterly report Aug 6, 2026 Jun 30, 2026
8-K Current report
Results of operations
Aug 6, 2026 Aug 6, 2026
8-K Current report
Other events
Jun 23, 2026 Jun 23, 2026
8-K Current report
Shareholder vote results
Jun 12, 2026 Jun 11, 2026
10-Q Quarterly report May 7, 2026 Mar 31, 2026
8-K Current report
Results of operations
May 7, 2026 May 7, 2026
8-K Current report
Officer or director change
Apr 28, 2026 Apr 28, 2026
ARS Annual report to shareholders Apr 28, 2026 Dec 31, 2025
DEFA14A Additional proxy material Apr 28, 2026 —
DEF 14A Proxy statement Apr 28, 2026 Jun 11, 2026
S-8 Employee stock plan registration Feb 26, 2026 —
10-K Annual report Feb 26, 2026 Dec 31, 2025
8-K Current report
Results of operations
Feb 26, 2026 Feb 26, 2026
8-K Current report
Material agreement, Regulation FD disclosure
Jan 22, 2026 Jan 21, 2026
10-Q Quarterly report Nov 6, 2025 Sep 30, 2025
8-K Current report
Results of operations
Nov 6, 2025 Nov 6, 2025
8-K Current report
Officer or director change
Sep 19, 2025 Sep 18, 2025
10-Q Quarterly report Aug 7, 2025 Jun 30, 2025
8-K Current report
Results of operations
Aug 7, 2025 Aug 7, 2025
8-K Current report
Shareholder vote results
Jun 13, 2025 Jun 11, 2025
10-Q Quarterly report May 8, 2025 Mar 31, 2025
8-K Current report
Results of operations
May 8, 2025 May 8, 2025
ARS Annual report to shareholders Apr 25, 2025 Apr 25, 2025
DEFA14A Additional proxy material Apr 25, 2025 —
DEF 14A Proxy statement Apr 25, 2025 Apr 25, 2025
S-8 Employee stock plan registration Feb 27, 2025 —
10-K Annual report Feb 27, 2025 Dec 31, 2024
8-K Current report
Results of operations
Feb 27, 2025 Feb 27, 2025
8-K Current report
Other events
Dec 5, 2024 Dec 4, 2024
424B5 Prospectus supplement Dec 5, 2024 —
424B5 Prospectus supplement Dec 3, 2024 —
8-K Current report
Regulation FD disclosure, Other events
Dec 2, 2024 Dec 2, 2024
10-Q Quarterly report Nov 6, 2024 Sep 30, 2024
8-K Current report
Results of operations
Nov 6, 2024 Nov 6, 2024
10-Q Quarterly report Aug 7, 2024 Jun 30, 2024
8-K Current report
Results of operations
Aug 7, 2024 Aug 7, 2024
8-K Current report
Officer or director change
Jul 22, 2024 Jul 19, 2024
8-K Current report
Shareholder vote results
Jun 28, 2024 Jun 26, 2024
DEFA14A Additional proxy material Jun 17, 2024 —
S-3ASR Automatic shelf registration May 8, 2024 —
10-Q Quarterly report May 8, 2024 Mar 31, 2024
8-K Current report
Results of operations
May 8, 2024 May 7, 2024
ARS Annual report to shareholders Apr 29, 2024 Dec 31, 2023
DEFA14A Additional proxy material Apr 29, 2024 —
DEF 14A Proxy statement Apr 29, 2024 Jun 26, 2024
S-8 Employee stock plan registration Mar 8, 2024 —
10-K Annual report Mar 8, 2024 Dec 31, 2023
8-K Current report
Results of operations
Mar 8, 2024 Mar 8, 2024
424B5 Prospectus supplement Feb 29, 2024 —
8-K Current report
Other events
Feb 29, 2024 Feb 28, 2024
FWP Free writing prospectus Feb 29, 2024 —
8-K Current report
Other events
Feb 28, 2024 Feb 28, 2024
424B5 Prospectus supplement Feb 28, 2024 —
8-K Current report
Other events
Feb 27, 2024 Feb 27, 2024
8-K Current report
Regulation FD disclosure
Feb 26, 2024 Feb 26, 2024
10-Q Quarterly report Nov 7, 2023 Sep 30, 2023
8-K Current report
Results of operations
Nov 7, 2023 Nov 7, 2023
10-Q Quarterly report Aug 8, 2023 Jun 30, 2023
8-K Current report
Results of operations, Other events
Aug 8, 2023 Aug 8, 2023
424B5 Prospectus supplement Jul 18, 2023 —
8-K Current report
Material agreement, Other events
Jul 18, 2023 Jul 17, 2023
FWP Free writing prospectus Jul 17, 2023 —
8-K Current report
Results of operations, Regulation FD disclosure, Other events
Jul 17, 2023 Jul 17, 2023
8-K Current report
Officer or director change
Jun 23, 2023 Jun 21, 2023
8-K Current report
Listing notice, Shareholder vote results
Jun 20, 2023 Jun 14, 2023
8-K Current report
Material agreement
May 9, 2023 May 9, 2023
424B5 Prospectus supplement May 9, 2023 —
10-Q Quarterly report May 9, 2023 Mar 31, 2023
8-K Current report
Results of operations
May 9, 2023 May 9, 2023
ARS Annual report to shareholders Apr 28, 2023 Dec 31, 2022
DEFA14A Additional proxy material Apr 28, 2023 —
DEF 14A Proxy statement Apr 28, 2023 Jun 14, 2023
8-K Current report
Officer or director change
Mar 31, 2023 Mar 27, 2023
S-8 Employee stock plan registration Mar 10, 2023 —
10-K Annual report Mar 10, 2023 Dec 31, 2022
8-K Current report
Results of operations
Mar 10, 2023 Mar 10, 2023
10-Q Quarterly report Nov 10, 2022 Sep 30, 2022
8-K Current report
Results of operations
Nov 10, 2022 Nov 10, 2022
8-K Current report
Officer or director change
Sep 22, 2022 Sep 21, 2022
EFFECT Filing Sep 19, 2022 —
CORRESP Letter to the SEC Sep 15, 2022 —
UPLOAD Letter from the SEC Aug 11, 2022 —
S-3 Shelf registration Aug 9, 2022 —
10-Q Quarterly report Aug 9, 2022 Jun 30, 2022
8-K Current report
Results of operations
Aug 9, 2022 Aug 9, 2022
8-K Current report
Shareholder vote results
Jun 15, 2022 Jun 14, 2022
10-Q Quarterly report May 10, 2022 Mar 31, 2022
8-K Current report
Results of operations
May 10, 2022 May 10, 2022
8-K Current report
Other events
May 2, 2022 May 2, 2022
DEFA14A Additional proxy material Apr 29, 2022 —
DEF 14A Proxy statement Apr 29, 2022 Jun 14, 2022
S-8 Employee stock plan registration Mar 18, 2022 —
10-K Annual report Mar 18, 2022 Dec 31, 2021
8-K Current report
Results of operations
Mar 18, 2022 Mar 18, 2022
10-Q Quarterly report Nov 9, 2021 Sep 30, 2021
8-K Current report
Results of operations
Nov 9, 2021 Nov 9, 2021
8-K Current report
Material agreement, New debt
Oct 1, 2021 Oct 1, 2021
8-K Current report
Officer or director change
Sep 9, 2021 Sep 7, 2021
8-K Current report
Material agreement, New debt
Aug 27, 2021 Aug 25, 2021
10-Q Quarterly report Aug 10, 2021 Jun 30, 2021
8-K Current report
Results of operations
Aug 10, 2021 Aug 10, 2021
8-K Current report
Officer or director change
Jul 16, 2021 Jul 15, 2021
8-K Current report
Bylaw or fiscal year change, Other events
Jun 15, 2021 Jun 15, 2021
S-8 Employee stock plan registration Jun 11, 2021 —
424B4 Prospectus Jun 11, 2021 —
EFFECT Filing Jun 10, 2021 —
S-1MEF Filing Jun 10, 2021 —
SEC STAFF LETTER Filing Jun 10, 2021 —
CERT Filing Jun 10, 2021 —
8-A12B Filing Jun 9, 2021 —
CORRESP Letter to the SEC Jun 9, 2021 —
CORRESP Letter to the SEC Jun 9, 2021 —
CORRESP Letter to the SEC Jun 7, 2021 —
S-1/A Amended registration statement Jun 7, 2021 —
SEC STAFF LETTER Filing Jun 1, 2021 —
UPLOAD Letter from the SEC May 28, 2021 —
CORRESP Letter to the SEC May 19, 2021 —
S-1 Registration statement May 19, 2021 —
UPLOAD Letter from the SEC May 14, 2021 —
SEC STAFF LETTER Filing May 12, 2021 —
D Filing Apr 30, 2021 —
DRS Filing Apr 16, 2021 —
D Filing Mar 12, 2021 —
D Filing Jul 14, 2020 —

Showing 126 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
JANX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
San Diego, CA
SEC filer status
Large accelerated filer
SEC CIK
1817713

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.